IPG Investment Advisors’s Matinas BioPharma MTNB Stock Holding History

IPG Investment Advisors’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,148	Closed	-$45K	–	169
2022 Q2	$45K	Buy	+1,148	New	+$43.8K	0.01%	145
2021 Q2	–	Sell	-648	Closed	-$34K	–	200
2021 Q1	$34K	Buy	+648	New	+$43.5K	0.01%	189
2019 Q3	–	Sell	-200	Closed	-$8.57K	–	145
2019 Q2	$8.57K	Sell	200 -650	-76%	-$31.2K	﹤0.01%	144
2019 Q1	$46.3K	Buy	850 +300	+55%	+$16.2K	0.02%	148
2018 Q4	$16.4K	Buy	+550	New	+$21.6K	0.01%	143
2017 Q4	–	Sell	-890	Closed	-$58.7K	–	162
2017 Q3	$58.7K	Buy	890 +100	+13%	+$6.67K	0.02%	140
2017 Q2	$66.8K	Buy	790 +100	+14%	+$13.4K	0.03%	133
2017 Q1	$95.6K	Buy	+690	New	+$113K	0.04%	128

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NRS

Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AWA

Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

IPG Investment Advisors's MTNB Position: Q3 2022 in Review

IPG Investment Advisors sold out of Matinas BioPharma (MTNB) in Q3 2022, closing a stake of 1,148 shares — an estimated $45K sold.

IPG Investment Advisors first reported a position in MTNB in Q1 2017 and held it in 8 quarters. The position peaked at $95.6K in Q1 2017. 55 funds tracked by Wall St. Rank hold MTNB as of Q3 2022.

IPG Investment Advisors reported no remaining Matinas BioPharma position as of Q3 2022 after selling out during the quarter.
IPG Investment Advisors sold 1,148 Matinas BioPharma shares in Q3 2022, an estimated $45K.
IPG Investment Advisors first reported a position in Matinas BioPharma in Q1 2017 and held it in 8 quarters.
IPG Investment Advisors's Matinas BioPharma position peaked at $95.6K in Q1 2017.
55 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2022.

Based on IPG Investment Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.